Amgen’s blinatumomab has
been granted orphan status by the
Therapeutic Goods Administration
(TGA) for a new indication as
treatment for the rare disease
named B-precursor acute
lymphoblastic leukemia.
Blinatumomab is available in
powder form for reconstitution.
CLICK HERE for TGA’s orphan page.The above article was sent to subscribers in Pharmacy Daily's issue from 11 Dec 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Dec 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.